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Abstract
Background: Maternal smoking during pregnancy is associated with adverse offspring health outcomes across
their life course. We hypothesize that DNA methylation is a potential mediator of this relationship.
Methods: We examined the association of prenatal maternal smoking with offspring blood DNA methylation in
2821 individuals (age 16 to 48 years) from five prospective birth cohort studies and perform Mendelian
randomization and mediation analyses to assess whether methylation markers have causal effects on disease
outcomes in the offspring.
Results: We identify 69 differentially methylated CpGs in 36 genomic regions (P value < 1 × 10−7) associated with
exposure to maternal smoking in adolescents and adults. Mendelian randomization analyses provided evidence for
a causal role of four maternal smoking-related CpG sites on an increased risk of inflammatory bowel disease or
schizophrenia. Further mediation analyses showed some evidence of cg25189904 in GNG12 gene mediating the
effect of exposure to maternal smoking on schizophrenia-related outcomes.
Conclusions: DNA methylation may represent a biological mechanism through which maternal smoking is
associated with increased risk of psychiatric morbidity in the exposed offspring.
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Background
Maternal smoking during pregnancy is associated with
increased risk for pre-term birth, fetal growth restriction,
and low birth weight [1–3], as well as neurodevelopmen-
tal impairments and respiratory and cardiovascular dis-
eases later in life [4–8]. Despite these well-known risks,
many women who commence pregnancy as smokers
continue to smoke throughout gestation. According to a
recent meta-analysis, the global prevalence of maternal
smoking during pregnancy varies widely from a few per-
centages up to nearly 40% in Ireland [9]. Thus, cigarette
smoking continues to be one of the most important
modifiable risk factors for the health of mothers and
their children.
Cigarette smoke is a potent environmental modifier of
DNA methylation [10]. In support of this, an
epigenome-wide meta-analysis of 13 birth cohort studies
identified over 6000 differentially methylated CpGs in
the cord blood of newborns exposed to prenatal smok-
ing [11]. Several smaller studies have suggested that
some of these methylation changes may persist across
childhood and adolescence into adulthood [12–15].
However, questions remain concerning whether such
DNA methylation changes endure across the life course
and whether they play a mediating role in linking pre-
natal smoke exposure to later life health outcomes.
Here, we combine data from five prospective birth co-
hort studies to investigate associations between prenatal
smoking exposure and offspring blood DNA methylation
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in 2821 adolescents and adults. We first examine the asso-
ciations of prenatal smoking exposure with DNA methyla-
tion in each cohort and then meta-analyze the results
across all studies. We focus on the > 6000 CpG sites previ-
ously identified in the cord blood of newborns exposed to
prenatal smoking [11]. We further (i) assess the impact of
current smoking by the participant on DNA methylation,
(ii) explore the dose-dependent effects of prenatal smok-
ing exposure on methylation at key CpG sites, (iii) exam-
ine the potential intrauterine effect of smoking exposure
on offspring DNA methylation by using paternal smoking
as a negative control, (iv) assess the persistence of DNA
methylation changes by investigating longitudinal associa-
tions from 30 to 48 years of age, and (v) conduct Mendel-
ian randomization (MR) and mediation analyses to
examine the potential causal effects of DNA methylation
changes on disease outcomes in the offspring (Fig. 1). Our
results show that prenatal smoking has persistent effects
on the offspring epigenome and provide evidence for a
causal role of DNA methylation in adverse health effects
that may arise from exposure to tobacco smoke in utero.
Results
Cohort-specific characteristics of the study participants
We analyzed the association of prenatal smoking exposure
with blood DNA methylation in altogether 1366 adoles-
cents (age 16 to 18 years) and 1455 adults (age 30 to 31
years). Of these, 1145 were from two independent North-
ern Finland Birth cohorts (NFBC1966 and NFBC1986),
257 were from the Isle of Wight Birth Cohort (IOWBC),
and 1419 from two Avon Longitudinal Study of Parents
and Children cohorts (ALSPAC mothers and ALSPAC
children). Additional file 1, Additional file 2, and Add-
itional file 3 show the characteristics of each study cohort.
Overall, 18.4% of the NFBC 1966 and 13.2% of the NFBC
1986 were prenatally exposed to maternal smoking. The
corresponding figures were 11.8% for ALSPAC children,
28.7% for ALSPAC mothers, and 16.3% for IOWBC.
DNA methylation meta-analysis
We found evidence for 69 differentially methylated
CpGs in 36 genomic regions (Table 1). All of these CpG
sites showed directionally concordant effects with previ-
ously reported associations in newborns [11], e.g., hyper-
methylation of cg04180046 in MYOG1 and cg05549655
in CYP1A1 and hypomethylation of cg05575921 in
AHRR and cg14179389 in GFI1 in the exposed offspring
compared with their unexposed counterparts.
Sensitivity and downstream analyses
To examine whether offspring’s own smoking had influ-
enced the results, we repeated the main analysis includ-
ing only those individuals who had never smoked
regularly in their life. The results were similar, in both
Fig. 1 Study design and analytical flow of the study. NFBC Northern Finland Birth Cohort, ALSPAC Avon Longitudinal Study of Parents and
Children (m = mothers, c = children), IWBC Isle of Wight Birth Cohort. Dagger symbol denotes CpG sites identified previously in the cord blood
of newborns exposed to maternal smoking in utero [11]. Asterisk denotes methylation data for persistence analysis
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Table 1 Association of exposure to maternal smoking during pregnancy and offspring peripheral blood DNA methylation
CpG Chr Position Gene β (SE) P value
cg04180046 7 45002736 MYO1G 0.045 (0.003) 2.60E−54
cg12803068 7 45002919 MYO1G 0.077 (0.005) 5.70E−45
cg22132788 7 45002486 MYO1G 0.045 (0.003) 6.80E−38
cg19089201 7 45002287 MYO1G 0.035 (0.003) 1.20E−31
cg05549655 15 75019143 CYP1A1 0.010 (0.001) 1.00E−28
cg25949550 7 145814306 CNTNAP2 − 0.007 (0.001) 5.40E−27
cg18493761 11 125386885 0.037 (0.004) 7.30E−21
cg15507334 10 14372913 FRMD4A 0.024 (0.003) 1.80E−20
cg14179389 1 92947961 GFI1 − 0.028 (0.003) 5.00E−20
cg00253658 16 54210496 0.037 (0.004) 3.40E−19
cg17924476 5 323794 AHRR 0.024 (0.003) 4.40E−19
cg13570656 15 75019196 CYP1A1 0.036 (0.004) 7.40E−19
cg11813497 10 14372879 FRMD4A 0.026 (0.003) 9.30E−19
cg22549041 15 75019251 CYP1A1 0.041 (0.005) 2.60E−18
cg05575921 5 373378 AHRR − 0.019 (0.002) 3.50E−18
cg12101586 15 75019203 CYP1A1 0.032 (0.004) 1.20E−17
cg18092474 15 75019302 CYP1A1 0.036 (0.004) 1.50E−17
cg11924019 15 75019283 CYP1A1 0.013 (0.002) 2.90E−16
cg25464840 10 14372910 FRMD4A 0.019 (0.002) 9.30E−16
cg00213123 15 75019070 CYP1A1 0.012 (0.002) 7.80E−15
cg11207515 7 146904205 CNTNAP2 − 0.023 (0.003) 1.00E−13
cg14157435 2 206628692 NRP2 − 0.046 (0.006) 1.10E−13
cg05348875 2 206628625 NRP2 − 0.040 (0.006) 7.60E−13
cg01952185 5 134813213 0.019 (0.003) 3.30E−12
cg22308949 2 206628553 NRP2 − 0.022 (0.003) 4.40E−12
cg05204104 2 235403141 ARL4C 0.017 (0.003) 4.80E−12
cg11641006 2 235213874 0.017 (0.003) 7.90E−12
cg09935388 1 92947588 GFI1 − 0.029 (0.004) 1.10E−11
cg05697249 11 111789693 C11orf52 0.015 (0.002) 1.30E−11
cg21161138 5 399360 AHRR − 0.013 (0.002) 1.50E−11
cg26681628 16 54210550 0.018 (0.003) 1.80E−11
cg11025974 2 152830521 CACNB4 0.016 (0.002) 9.10E−11
cg15016771 2 235403218 ARL4C 0.008 (0.001) 1.00E−10
cg11429111 5 134813329 0.014 (0.002) 1.30E−10
cg25189904 1 68299493 GNG12 − 0.020 (0.003) 1.30E−10
cg06758350 21 36259460 RUNX1 0.030 (0.005) 1.70E−10
cg17852385 15 75019188 CYP1A1 0.010 (0.002) 2.60E−10
cg01664727 21 36258423 RUNX1 0.027 (0.004) 2.60E−10
cg20344448 10 14372431 FRMD4A 0.014 (0.002) 2.80E−10
cg00794911 6 166260532 − 0.012 (0.002) 5.20E−10
cg22698744 21 36263808 RUNX1 0.023 (0.004) 7.30E−10
cg03142697 21 36258497 RUNX1 0.016 (0.003) 8.10E−10
cg14563637 9 98931801 0.016 (0.003) 1.20E−09
cg15091747 21 36262896 RUNX1 0.014 (0.002) 1.20E−09
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direction and magnitude, across all 36 genomic regions
as in the full meta-analysis (Fig. 2), indicating that the
association between maternal smoking and blood DNA
methylation was not mediated through offspring’s own
smoking behavior.
We then examined the dose-response relationship be-
tween maternal smoking and blood DNA methylation in
the offspring. Methylation differences between the ex-
posed and unexposed offspring became larger with in-
creased smoking intensity across most CpG sites, e.g.,
each additional three cigarettes smoked per day during
pregnancy was associated with 0.23 standard deviation
(SD) increase in methylation level in cg05549655 in
CYP1A1 gene (Table 2). Figure 3 shows the visual repre-
sentations of the dose-response effect of maternal smok-
ing on offspring blood DNA methylation of top CpGs in
four top loci.
To assess potential unmeasured confounding and to
establish a causal intrauterine effect between maternal
smoking and the offspring DNA methylation, we used
paternal smoking as a negative control. Maternal smok-
ing and paternal smoking showed similar directions of
effect; however, the effect estimates for exposure to pa-
ternal smoking were considerably smaller (Table 2).
Adjusting for paternal smoking had no significant effect
on maternal smoking estimates (Additional file 4).
We performed a longitudinal analysis to examine
whether the maternal smoking-associated alterations in
DNA methylation persisted from early adulthood (age
30–31 years) into midlife (age 46–48 years) in the NFBC
1966 and ALSPAC mothers’ cohorts. We found no evi-
dence for change in direction or magnitude of associa-
tions in blood DNA methylation between the two time
points (Fig. 4), suggesting that DNA methylation levels
Table 1 Association of exposure to maternal smoking during pregnancy and offspring peripheral blood DNA methylation
(Continued)
CpG Chr Position Gene β (SE) P value
cg12984635 19 44032076 ETHE1 0.015 (0.002) 2.20E−09
cg01825213 9 98979965 0.019 (0.003) 2.50E−09
cg12477880 21 36259241 RUNX1 0.038 (0.006) 2.80E−09
cg17199018 8 28206278 ZNF395 − 0.017 (0.003) 3.90E−09
cg00174179 3 49450293 RHOA;TCTA − 0.006 (0.001) 7.00E−09
cg15578140 7 147718109 MIR548F3;CNTNAP2 0.011 (0.002) 7.50E−09
cg14540913 9 132458514 PRRX2 0.013 (0.002) 7.60E−09
cg18132363 6 166260572 − 0.019 (0.003) 7.60E−09
cg21253335 5 87835928 0.017 (0.003) 1.30E−08
cg25879142 7 4671391 0.018 (0.003) 1.80E−08
cg11845417 11 111789613 C11orf52 0.011 (0.002) 2.40E−08
cg20117519 7 8429907 0.022 (0.004) 2.40E−08
cg05783384 2 218843735 0.021 (0.004) 2.60E−08
cg13822849 9 137999757 OLFM1 0.007 (0.001) 2.90E−08
cg16449012 4 17781880 FAM184B 0.014 (0.002) 3.10E−08
cg05634495 6 122364658 0.016 (0.003) 3.10E−08
cg08644678 4 17711202 FAM184B 0.009 (0.002) 3.10E−08
cg13834112 15 90361639 0.013 (0.002) 3.60E−08
cg06635952 2 70025869 ANXA4 0.011 (0.002) 5.50E−08
cg14485097 7 4671479 0.016 (0.003) 7.40E−08
cg04598670 7 68697651 − 0.019 (0.003) 8.30E−08
cg03252786 11 125106056 PKNOX2 0.006 (0.001) 8.70E−08
cg04749740 2 65935124 0.015 (0.003) 9.20E−08
cg15325070 1 2792704 0.014 (0.003) 9.20E−08
cg04358214 16 67143304 C16orf70 0.022 (0.004) 9.60E−08
The analyses were conducted separately in each participating cohort adjusted for study-specific covariates as necessary, and combined using inverse-variance
weighted fixed-effects meta-analysis
Chr chromosome, β effect size estimate, SE standard error
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remain relatively stable for several decades after prenatal
exposure to maternal smoking.
Mendelian randomization analysis
We estimated the causal effects of DNA methylation
changes on disease outcomes using MR. We extracted
the effect sizes of SNP-CpG associations for the 69 dif-
ferentially methylated CpGs available in the Accessible
Resource for Integrated Epigenomic Studies (ARIES)
mQTL database [16] (http://www.mqtldb.org/) and
found strong instruments for 15 CpG sites. Of these 15
CpG sites, three (cg15578140 in microRNA 548f-3
(MIR548F3), cg09935388 in Growth Factor Independent
Protein 1 (GFI1), cg04598670 (unknown gene)) showed
potential causal associations with inflammatory bowel
diseases and one (cg25189904 in Guanine Nucleotide
Binding Protein Gamma 12 (GNG12)) with schizophre-
nia (PFDR < 0.05, Table 3).
Mediation analysis
We then sought to test whether methylation changes
in these four CpGs mediated the association between
maternal smoking and disease outcomes. However,
since the prevalence of inflammatory bowel disease is
relatively low in the general population, we assessed
the associations of maternal smoking and CpGs on ir-
ritable bowel syndrome (IBS), which is a constellation
of functional gastrointestinal disorder symptoms.
These data were obtained from self-administered
questionnaires in NFBC1966 at 46 years [17]. Preva-
lence of schizophrenia is also low in the general popu-
lation. Therefore, instead of diagnosed schizophrenia,
we used personality trait scales measuring schizotypal
and affective symptoms as an outcome. Such personal-
ity scales were derived from questionnaires available
in the NFBC 1966 data at 31 years, and they can be
used to identify subjects with latent personality with
genetic vulnerability for schizophrenia [18]. We found
Fig. 2 Comparison of meta-analysis effect size estimates and their 95% confidence intervals in all participants (x-axis) and never-smokers (y-axis)
for the 36 top CpG sites. All effect size estimates are adjusted for study-specific covariates as necessary and meta-analyzed using inverse-variance
weighted fixed-effects model
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Table 2 Association results for the leading CpG sites from each locus selected for the sensitivity and downstream analyses
Meta-analysis Sensitivity and downstream analyses
5 studies, N = 2821 Never-smokers, N = 1298 Paternal smoking, N = 1774 Dose-response analysis, N = 1134
CpG Chr Gene β SE P value β SE P value β SE P value β SE P value
cg15325070 1 0.014 0.003 9.23E−08 0.009 0.004 1.92E−02 0.000 0.003 9.16E−01 0.168 0.034 6.81E−07
cg25189904 1 GNG12 − 0.020 0.003 1.28E−10 − 0.018 0.004 1.87E−05 − 0.004 0.003 1.52E−01 − 0.146 0.032 5.85E−06
cg14179389 1 GFI1 − 0.028 0.003 5.00E−20 − 0.027 0.004 1.07E−09 − 0.004 0.003 1.77E−01 − 0.214 0.031 4.92E−12
cg04749740 2 0.015 0.003 9.21E−08 0.015 0.004 9.64E−04 0.004 0.003 1.03E−01 0.061 0.034 6.98E−02
cg06635952 2 ANXA4 0.011 0.002 5.54E−08 0.011 0.003 1.88E−04 0.001 0.002 9.53E−01 0.073 0.029 1.12E−02
cg11025974 2 CACNB4 0.016 0.002 9.06E−11 0.018 0.004 1.57E−07 − 0.001 0.002 6.41E−01 0.169 0.033 2.19E−07
cg14157435 2 NRP2 − 0.046 0.006 1.15E−13 − 0.042 0.008 6.01E−07 − 0.014 0.006 2.80E−02 − 0.201 0.033 9.33E−10
cg05783384 2 0.021 0.004 2.59E−08 0.014 0.005 1.15E−02 0.003 0.004 3.92E−01 0.097 0.033 3.26E−03
cg05204104 2 ARL4C 0.017 0.003 4.81E−12 0.016 0.004 6.02E−05 0.006 0.003 7.96E−02 0.036 0.033 2.73E−01
cg00174179 3 RHOA − 0.006 0.001 7.01E−09 − 0.006 0.002 3.22E−04 − 0.002 0.001 5.21E−02 − 0.104 0.029 3.89E−04
cg16449012 4 FAM184B 0.014 0.002 3.10E−08 0.021 0.004 4.42E−08 0.003 0.002 1.62E−01 0.119 0.03 7.81E−05
cg05575921 5 AHRR − 0.019 0.002 3.53E−18 − 0.011 0.003 1.19E−04 − 0.008 0.003 2.75E−03 − 0.134 0.027 5.91E−07
cg21253335 5 0.017 0.003 1.25E−08 0.014 0.004 1.12E−03 0.004 0.003 1.17E−01 0.108 0.033 1.04E−03
cg01952185 5 0.019 0.003 3.31E−12 0.017 0.004 5.81E−05 0.005 0.003 4.49E−02 0.128 0.03 1.67E−05
cg05634495 6 0.016 0.003 3.14E−08 0.014 0.005 2.54E−03 0.002 0.003 5.00E−01 0.088 0.033 6.86E−03
cg00794911 6 − 0.012 0.002 5.20E−10 − 0.007 0.003 1.25E−02 − 0.005 0.002 1.15E−02 − 0.115 0.034 6.42E−04
cg25879142 7 0.018 0.003 1.79E−08 0.013 0.004 3.05E−03 0.003 0.003 3.73E−01 0.121 0.031 1.23E−04
cg20117519 7 0.022 0.004 2.39E−08 0.022 0.006 1.70E−04 0.007 0.004 4.08E−02 0.112 0.033 6.72E−04
cg19089201 7 MYO1G 0.035 0.003 1.18E−31 0.030 0.004 5.75E−12 0.007 0.003 1.51E−02 0.225 0.032 2.24E−12
cg04598670 7 − 0.019 0.003 8.33E−08 − 0.016 0.005 4.54E−03 − 0.007 0.003 3.95E−02 − 0.178 0.034 1.54E−07
cg25949550 7 CNTNAP2 − 0.007 0.001 5.41E−27 − 0.007 0.001 1.45E−14 − 0.002 0.001 6.57E−03 − 0.157 0.022 1.65E−12
cg11207515 7 CNTNAP2 − 0.023 0.003 1.03E−13 − 0.020 0.004 2.75E−06 − 0.011 0.003 2.46E−04 − 0.145 0.032 7.02E−06
cg15578140 7 MIR548F3 0.011 0.002 7.54E−09 0.014 0.003 7.89E−06 − 0.001 0.002 5.70E−01 0.152 0.031 1.12E−06
cg17199018 8 ZNF395 − 0.017 0.003 3.85E−09 − 0.016 0.004 7.10E−05 − 0.003 0.003 3.10E−01 − 0.121 0.033 2.63E−04
cg14563637 9 0.016 0.003 1.19E−09 0.016 0.004 9.26E−05 0.003 0.002 1.69E−01 0.092 0.031 3.26E−03
cg14540913 9 PRRX2 0.013 0.002 7.57E−09 0.015 0.003 1.81E−05 0.001 0.002 5.79E−01 0.148 0.032 2.62E−06
cg13822849 9 OLFM1 0.007 0.001 2.87E−08 0.007 0.002 5.84E−05 0.003 0.002 2.90E−02 0.126 0.03 3.24E−05
cg11813497 10 FRMD4A 0.026 0.003 9.27E−19 0.022 0.004 1.46E−07 − 0.001 0.003 6.26E−01 0.117 0.032 2.81E−04
cg05697249 11 C11orf52 0.015 0.002 1.30E−11 0.015 0.003 8.68E−06 0.003 0.002 1.54E−01 0.136 0.035 8.25E−05
cg18493761 11 0.037 0.004 7.30E−21 0.032 0.006 4.99E−08 0.008 0.004 2.60E−02 0.154 0.034 4.82E−06
cg05549655 15 CYP1A1 0.010 0.001 1.04E−28 0.009 0.001 6.03E−13 0.002 0.001 4.28E−02 0.230 0.028 1.92E−16
cg13834112 15 0.013 0.002 3.55E−08 0.018 0.004 6.39E−07 0.001 0.002 8.10E−01 0.120 0.031 1.24E−04
cg00253658 16 0.037 0.004 3.44E−19 0.032 0.006 6.54E−08 0.005 0.005 2.81E−01 0.166 0.033 4.83E−07
cg04358214 16 C16orf70 0.022 0.004 9.56E−08 0.021 0.006 5.93E−04 0.005 0.004 2.42E−01 0.090 0.031 3.94E−03
cg12984635 19 ETHE1 0.015 0.002 2.17E−09 0.014 0.003 5.87E−05 0.001 0.002 7.33E−01 0.116 0.031 1.49E−04
cg06758350 21 RUNX1 0.030 0.005 1.68E−10 0.016 0.007 2.03E−02 0.002 0.005 7.09E−01 0.140 0.034 3.92E−05
The analyses were conducted separately in each participating cohort, adjusted for study-specific covariates as necessary, and combined using inverse-variance
weighted fixed-effects meta-analysis. The effect size estimates for the dose-response analysis represent the difference in blood DNA methylation (in standard
deviation units) per three additional cigarettes smoked per day in pregnancy
Chr chromosome, β effect size estimate, SE standard error
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evidence for cg25189904 mediating the association be-
tween exposure to maternal smoking and Bipolar II
Scale (P = 0.024) and Hypomanic Personality Scale (P
= 0.018) (Fig. 5a and b). The estimated mediated pro-
portions were 30% and 28%, respectively (Additional
file 5). We did not find evidence for a mediating effect
of blood DNA methylation on IBS (P > 0.3 for all
CpGs, Additional file 5).
Discussion
We combined data from five studies in adolescents and
adults to examine the association between maternal
smoking during pregnancy and blood DNA methyla-
tion in the offspring from 16 to 48 years of age. We
identified 69 differentially methylated CpGs in 36
genomic regions. The top differentially methylated
CpG sites showed a clear dose-response relationship
Fig. 3 Visualization of the dose-response effect of the intensity of maternal smoking in pregnancy (x-axis) on offspring blood DNA methylation (y-
axis) for top four CpG sites in four gene regions (AHRR, CYP1A1, MYO1G, GFI1). Prediction estimates and their 95% confidence intervals plotted
based on generalized additive mixed models, with other covariates (offspring sex, body mass index, smoking status, population stratification, and
technical covariates) set at their mean (continuous variables) or mode (categorical variables). The density plots represent the distribution of the
cigarettes smoked per day in pregnancy. The plots are truncated at five cigarettes per day in pregnancy (containing 94% of full data)
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with number of cigarettes smoked during pregnancy.
The associations observed in adulthood were robust
to adjustment for multiple potential confounding fac-
tors and persisted into middle age with no significant
change in direction and magnitude of associations.
Mendelian randomization and mediation analyses sug-
gested that alterations in DNA methylation may link
maternal smoking during pregnancy to increased risk
of psychiatric morbidity and potentially with inflam-
matory bowel disease in the exposed offspring.
Fig. 4 Longitudinal analysis of association between exposure to maternal smoking and offspring blood DNA methylation. Effect size estimates
(adjusted for study-specific covariates and meta-analyzed using inverse-variance weighted fixed-effects model) and their 95% confidence intervals
at age 30–31 years (red) and age 46–48 years (blue) for top CpG sites and P values for the test of equality of the effect size estimates
Table 3 Mendelian randomization analysis of top differentially methylated CpGs tested against 106 diseases
Exposure Gene Disease β SE P value FDR P value Unit
cg15578140 MIR548F3 Inflammatory bowel disease − 0.104 0.018 3.73E−09 2.54E−07 Log odds
cg09935388 GFI1 Inflammatory bowel disease − 0.152 0.034 7.27E−06 2.18E−04 Log odds
cg04598670 Unknown Inflammatory bowel disease − 0.410 0.091 7.27E−06 5.24E−04 Log odds
cg09935388 GFI1 Crohn’s disease − 0.162 0.040 4.74E−05 7.12E−04 Log odds
cg04598670 Unknown Crohn’s disease − 0.439 0.108 4.74E−05 1.71E−03 Log odds
cg09935388 GFI1 Ulcerative colitis − 0.160 0.042 1.47E−04 1.47E−03 Log odds
cg04598670 Unknown Ulcerative colitis − 0.433 0.114 1.47E−04 3.52E−03 Log odds
cg25189904 GNG12 Schizophrenia − 0.222 0.053 3.37E−05 1.82E−03 Log odds
Only significant associations (PFDR < 0.05) are shown
GFI1 growth factor independent protein 1, MIR548F3 microRNA 548f-3, GNG12 guanine nucleotide binding protein gamma 12, β effect size estimate, SE standard
error FDR false discovery rate
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The findings of our study confirm and extend the re-
sults of earlier reports by demonstrating that maternal
smoking during pregnancy is associated with alterations
in offspring blood DNA methylation not only in new-
borns [11, 19, 20], children, and adolescents [12, 13], but
also in adults, several decades following the exposure.
The similarity in differentially methylated CpG sites and
the consistency in direction of methylation changes be-
tween our study and earlier EWAS imply that the smoke
exposure-induced methylation changes may be soma-
wide and persist throughout life. However, the effects of
smoking may also be targeted to specific regions of the
epigenome, as indicated by the observations that both
prenatal smoke exposure and active smoking affect the
methylation patterns of same gene regions, e.g., AHRR
and CYP1A1, which are involved in chemical detoxifica-
tion [10]. Because of these similar effects, the methyla-
tion changes found in people exposed to prenatal
smoking may also reflect current or past smoking by
the people themselves or some other passive smok-
ing exposure. Adjusting for offspring active smoking
did not substantially change the results in the
present study. However, parental smoking is known
to associate with their offspring’s smoking behavior
also via genetic predisposition [21, 22] and thus own
smoking may serve as a mediator on the path be-
tween maternal smoking and DNA methylation.
Therefore, simply adjusting for own smoking can
lead to erroneous conclusions about the direct ef-
fects of maternal smoking [23]. We therefore per-
formed a sensitivity analysis including only offspring
who themselves had never smoked in their life and
found that the associations were similar across all
CpG sites as in the full meta-analysis.
We also used paternal smoking as a negative control
by comparing the associations of maternal smoking dur-
ing pregnancy and paternal smoking with offspring
methylation and found that the effect estimates were
substantially greater for maternal smoking, and adjusting
for paternal smoking had virtually no effect on maternal
smoking estimates. This indicates it is unlikely that the
associations between maternal smoking and offspring
methylation were attributable to post-natal passive
smoking exposure or some unmeasured confounding.
These results together with the finding of a clear dose-
dependent relationship of methylation with increased
smoking intensity during pregnancy suggest a direct bio-
logical effect of in utero exposure to cigarette smoke on
DNA methylation.
The longitudinal analysis showed that differentially
methylated CpGs observed around age 30 persisted into
middle age (around age 48) without significant change
in direction or magnitude of methylation levels. This
corroborates the findings of recent smaller studies,
which found several differently methylated CpGs in
middle-aged women exposed to maternal smoking in
utero [14, 15], and suggests that some of the prenatal
smoking exposure-associated methylation changes are
largely irreversible and unaffected by age and/or envir-
onmental exposures later in life. To assess whether such
persistent changes in DNA methylation are causally im-
plicated with disease, we performed a Mendelian
randomization analysis using summary data from large
genome-wide association studies [24]. We found evi-
dence for potential causal associations for three CpGs
(cg15578140, cg09935388, cg04598670) with inflamma-
tory bowel disease and one CpG (cg25189904) with
schizophrenia. To strengthen the evidence for these
Fig. 5 Mediation analysis examining the indirect effect of maternal smoking during pregnancy on Bipolar II Scale (a) and Hypomanic personality
scale (b) through differential methylation of cg25189904 in GNG12. Data are shown as beta estimate for effect size and 95% confidence intervals
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potentially causal associations, we also performed a for-
mal mediation analysis in the NFBC1966 cohort and
found evidence for differential methylation in
cg25189904 mediating the association between maternal
smoking and Bipolar II Scale and Hypomanic Personality
Scale, explaining 30% and 28% of the total effect, re-
spectively. These results corroborate the findings of pre-
vious observational studies that maternal smoking
during pregnancy is associated with increased risk of
psychiatric morbidity in the exposed offspring [25–28].
However, we found no evidence for mediating effect of
differential methylation cg15578140, cg09935388, and
cg04598670 in the association of maternal smoking and
irritable bowel syndrome. Such discrepant results could
be due to relatively small sample size in the mediation
analysis, or because the irritable bowel syndrome is not
a good proxy for inflammatory bowel disease, or because
the causal effect estimates for inflammatory bowel dis-
ease in the MR analysis were biased due to, for example,
pleiotropic effects of genetic instruments on the out-
come. Thus, additional studies are needed to assess
whether prenatal smoking is associated with increased
risk of inflammatory bowel disease in the exposed off-
spring and whether alterations in DNA methylation me-
diates this association.
Our results may provide insights into potential mecha-
nisms linking prenatal smoking exposure to psychiatric
disorders. Experimental studies suggest that GNG12 is
an important regulator of inflammatory signaling in
microglia cells, which are the resident macrophages of
the central nervous system [29]. A role of inflammation
in the etiology of schizophrenia and psychotic illness has
been suggested [30, 31], and in line with this, a large
meta-analysis of 2424 cases and over 1.2 million controls
indicated that childhood central nervous system infec-
tions are associated with nearly twofold risk of schizo-
phrenia in adulthood [32]. Our DNA methylation data
were from the whole blood while the pathogenic pro-
cesses for psychiatric disorders, including schizophrenia,
occur primarily in brain tissue. We believe that methyla-
tion in blood mirrors the corresponding sites in disease-
relevant tissues [33]. Such mirror sites can occur if the
exposure occurs during early stages of prenatal develop-
ment, thus affecting multiple tissues [33]. Therefore,
blood DNA methylation may act as a marker for differ-
ential DNA methylation in the primary disease tissue
that is mediating the effects of intrauterine smoke ex-
posure. There is support justifying the use of blood sam-
ples to discover genes related to brain phenotypes and
diseases [34]. However, further studies are needed to val-
idate our findings and investigate the biological rele-
vance of GNG12 in the corresponding tissue.
Our study has both strengths and limitations. The
large sample size of males and females and similar ages
from different cohorts enabled us to obtain precise esti-
mate of the long-term effects of maternal smoking on
DNA methylation. Several downstream analyses and use
of paternal smoking as a negative control allowed us to
distinguish the associations from potential confounding,
and the follow-up analysis from young adulthood to
middle age allowed us to examine the persistence of
methylation changes. The limitations are that we did not
have tissue-specific DNA methylation data as indicated
above and that maternal smoking was determined from
self-reported questionnaires. As self-reports may be
biased by under-reporting or recall bias, our findings
may underestimate true effects. In the ALSPAC mothers’
cohort, the adult offspring reported their mothers’ smok-
ing, although this could also be subject to recall bias.
False reporting may also concern the adolescents in our
study since they might have been reluctant to disclose
their true smoking behavior, although in the IOWBC
adolescent smoking was confirmed by urinary cotinine
measurement. Another limitation is that the subjects in
the ALSPAC children and ALSPAC mothers’ cohorts are
related individuals. However, excluding either one of the
related ALSPAC data sets did not notably affect the re-
sults (data not shown).
Conclusions
Maternal smoking during pregnancy has long-lasting ef-
fects on offspring epigenome. DNA methylation may
represent a biological mechanism through which mater-
nal smoking is associated with increased risk of psychi-
atric morbidity and potentially inflammatory bowel
disease in the exposed offspring.
Methods
Study cohorts
Northern Finland Birth Cohort 1966
The Northern Finland Birth Cohort 1966, previously de-
scribed in detail [35, 36], targeted all pregnant women,
residing in the two northernmost provinces of Finland
with expected dates of delivery between 1 January and
31 December 1966. Over 96% of eligible women partici-
pated in the study, thus comprising 12,055 mothers
followed prospectively on average from 16th gestational
week and 12,058 live-born children. In 1997, at offspring
age of 31 years, all cohort participants with known ad-
dresses were sent a postal questionnaire on health and
lifestyle and those living in Northern Finland or Helsinki
area were invited to a clinical examination which in-
cluded blood sampling. In total, both questionnaire and
clinical data were collected for 6007 participants. DNA
was successfully extracted for 5753 participants from
fasted blood samples [37]. In 2012, all individuals with
known address in Finland were sent postal question-
naires and an invitation for clinical examination. Both
Wiklund et al. Clinical Epigenetics           (2019) 11:97 Page 10 of 16
questionnaire and clinical data was collected for 5539
participants. DNA methylation at 31 years was extracted
for 807 randomly selected subjects of whom both ques-
tionnaire and clinical data with cardio-metabolic mea-
sures were available at both 31 and 46 years. Of these
individuals, DNA methylation data at 46 years was ex-
tracted for 766 subjects.
Northern Finland Birth Cohort 1986
The Northern Finland Birth Cohort 1986 includes all
mothers (prospective data collection from 10th gesta-
tional week) with children whose expected date of deliv-
ery fell between July 1, 1985, and June 30, 1986, in the
two northernmost provinces of Finland (99% of all births
during that time) [38]. The cohort consists of 9362
women and 9432 live-born children. In 2001, all individ-
uals with known address received a postal questionnaire
on health and lifestyle and invitation to a clinical exam-
ination. DNA were extracted from fasting blood samples,
and DNA methylation was measured for 546 randomly
selected subjects with full data available.
In both NFBC cohorts, complete data included single-
ton births and subjects with complete set clinical follow-
up and DNA methylation data, excluding subjects with
missing information and twins. A written informed con-
sent for the use of the data including DNA was obtained
from all study participants and their parents. Ethical ap-
proval for the study was received from Ethical Commit-
tee of Northern Osthrobothnia Hospital District and
Oulu University, Faculty of Medicine.
Isle of Wight Birth Cohort
Isle of Wight Birth Cohort is a general population-based
birth cohort recruited on the Isle of Wight in 1989 to as-
sess the role of heredity and environment on develop-
ment of allergic disorders and allergen sensitization. The
details of this birth cohort have been described in previ-
ous reports [39]. In brief, both the Isle of Wight and the
study population are 99% Caucasian. Ethics approvals
were obtained from the Isle of Wight Local Research
Ethics Committee (now named the National Research
Ethics Service, NRES Committee South Central—
Southampton B) at recruitment and for the 1, 2, 4,
10, and 18 years follow-up. Exact age at 18-year
follow-up was calculated from the date of blood sam-
ple collection for the 18-year follow-up and the date
of birth. DNA methylation in peripheral blood sam-
ples was analyzed from randomly selected subjects (n
= 257) at the 18-year follow-up.
Avon Longitudinal Study of Parents and Children
Pregnant women resident in the former county of
Avon, UK, with expected dates of delivery 1 April 1991
to 31 December 1992 were invited to take part in the
study. The initial number of pregnancies enrolled is 14,
541 (for these at least one questionnaire has been
returned or a “Children in Focus” clinic had been
attended by 19 July 1999). Of these initial pregnancies,
there was a total of 14,676 fetuses, resulting in 14,062
live births and 13,988 children who were alive at 1 year
of age [40, 41].
The Accessible Resource for Integrated Epigenomic
Studies (ARIES) is a sub study of ALSPAC, which in-
cludes 1018 mothers and their children for whom
methylation data has been created [42]. The ARIES par-
ticipants were selected based on the availability of DNA
samples at two time points for the women (antenatal
[mean age 30 years] and at follow-up [mean age 48
years] when the offspring were adolescents) and three
time points for their offspring (neonatal, childhood
[mean age 7.5 years], and adolescence [mean age 17.1
years]). A web portal allows openly accessible browsing
of aggregate ARIES DNA methylation data (ARIES-Ex-
plorer) (http://www.ariesepigenomics.org.uk/). Please
note that the study website contains details of all the
data that is available through a fully searchable data
dictionary and variable search tool: http://www.bristol.
ac.uk/alspac/researchers/our-data/. Ethical approval for
the study was obtained from the ALSPAC Ethics and
Law Committee and the Local Research Ethics
Committees.
Definition of maternal smoking during pregnancy
In NFBCs and ALSPAC studies, expectant mothers
were asked whether they had smoked cigarettes before
or at the beginning of the pregnancy, how many years
they had smoked, the number of cigarettes smoked per
day, and whether they had changed their smoking
habits during the pregnancy. Offspring were considered
to be prenatally exposed to cigarette smoking if mother
reported smoking regularly (at least one cigarette per
day) from pregnancy week 8 onwards. The ALSPAC
mothers were also asked whether their mothers had
smoked and were asked whether they had smoked
when they were pregnant with them. In the IOWBC,
maternal smoking status in pregnancy was self-reported
and defined as any smoking in pregnancy or no smok-
ing during pregnancy.
Measurement of DNA methylation
Methylation of genomic DNA was quantified using the
Illumina HumanMethylation450 array (ALSPAC, ARIES,
IOWBC, and NFBC1966 at age 31, NFBC1986) or Illu-
mina EPIC array (NFBC1966 at age 46) according to the
manufacturer’s instructions. Bisulfite conversion of gen-
omic DNA was performed using the EZ DNA methyla-
tion kit according to the manufacturer’s instructions
(Zymo Research, Orange, CA).
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Quality control of methylation data
In NFBCs and IOWBC, quality control and quantile
normalization for DNA methylation data were adapted
from the CPACOR pipeline [43]. Illumina Background
Correction was applied to the intensity values, a detection
P value threshold was set at P < 10−16, and samples with
call rate < 98% were excluded. Quantile normalization was
done separately for six probe-type categories, and these
normalized intensity values were used to calculate the
methylation beta value at each CpG site, ranging between
0 (no methylation) and 1 (full methylation). Probes with
call rate < 95% were excluded from the analyses. A princi-
pal component analysis (PCA) was carried out for array
control probes, and the first 30 principal components
(PCs) were used as explanatory variables in the subse-
quent regression models [43]. White blood cell subpopu-
lation estimates were obtained using the software
provided by Houseman et al. [44], and these estimates
were also added as covariates in the regression models. In
ARIES, the DNA methylation wet-laboratory and pre-
processing analyses were performed as previously de-
scribed [42]. In brief, samples from all time points were
distributed across slides using a semi-random approach to
minimize the possibility of confounding by batch effects.
Samples failing quality control (average probe P value ≥
0.01, those with sex or genotype mismatches) were ex-
cluded from further analysis and scheduled for repeat
assay, and probes that contained < 95% of signals detect-
able above background signal (detection P value < 0.01)
were excluded from the analysis. Methylation data were
pre-processed using R software, with background correc-
tion and subset quantile normalization performed using
the pipeline described by Touleimat and Tost [45].
Statistical analyses
Meta-analysis of 6073 CpG sites in five studies
Study design and analytical flow of the study are shown
in Fig. 1, and the data availability for each analysis is pre-
sented in Table 4. All analyses were conducted using R
software [46]. Linear regression was used to examine the
association between sustained maternal smoking during
pregnancy (from pregnancy week 8 onwards) and
offspring peripheral blood DNA methylation at 6073
CpG sites that were previously identified to be differen-
tially methylated in newborns exposed to maternal
smoking in utero in recent epigenome-wide association
study (EWAS) (false discovery rate-corrected P value <
0.05) [11]. The final model was adjusted for study-
specific covariates as necessary (offspring’s sex, BMI,
smoking status, and social class for IOWBC; additionally
first four genetic PCs for NFBC cohorts; offspring age,
maternal age, and social class for ALSPAC cohorts). The
model was run independently in each study, and the re-
sults were then meta-analyzed over all five studies
(NFBC1986 (age 16 years), NFBC1966 (age 31 years),
IOWBC (age 18 years), ALSPAC mothers (age 30 years)
and ALSPAC children (age 17 years)) using an inverse
variance weighted fixed-effects model. Statistical signifi-
cance level was set at P < 1 × 10−7, which corresponds
approximately to a Bonferroni-corrected significance
level of 0.05 for 450,000 independent tests. Such a con-
servative threshold was robust, and thus, the significant
probes were considered worthy of further examination in
a series of sensitivity and downstream analyses. The lead-
ing CpG site from each gene region (1-Mb window cen-
tered on the CpG site with the strongest association) was
selected for these analyses.
We note that ALSPAC children were part of the earl-
ier study from where the 6073 CpG sites were selected
[11]. However, the earlier study examined DNA methyla-
tion in the cord blood, whereas the current study uses
blood DNA methylation data from the same cohort at
17 years. If the associations with exposure to maternal
smoking in cord blood DNA methylation were due to
confounding, we would not expect the signal to persist
until adolescence. Furthermore, removal of the ALSPAC
children from the meta-analysis made no material differ-
ence to the effect size estimates (data not shown).
Sensitivity analyses
Impact of offspring's own smoking on their DNA
methylation
To assess the impact of participants’ own smoking on
methylation level by maternal smoking exposure, the
Table 4 Data availability in each study for different analyses
Sensitivity and downstream analyses for top CpG sites











at the 2nd time point)
NFBC1986 16 Yes Yes Yes Yes No
NFBC1966 31 Yes Yes Yes Yes Yes (46 years)
ALSPAC mothers 30 Yes Yes No No Yes (48 years)
ALSPAC children 17 Yes Yes Yes No No
IOWBC 18 Yes Yes No No No
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same regression model was run excluding all partici-
pants who reported smoking regularly, defined in
NFBC1966 and NFBC1986 as smoking at least one
cigarette per day for 1 year or more during their life. In
the ALSPAC mothers’ cohort, smoking behavior was
queried at two time points. At age 30 years, women were
asked whether they had smoked regularly before preg-
nancy. At age 48 years, women were asked whether they
were current or former smokers, and in case of the lat-
ter, whether they had smoked every day. From these
data, a dichotomous variable for any smoking for each
of the time points was derived. In the IOWBC, partici-
pant’s own smoking status was defined as having ever or
never smoked asked via a questionnaire administered at
age 18 years. The model was run independently in each
study with the same covariates as above (excluding ad-
justment for offspring’s smoking as all individuals were
non-smokers) and meta-analyzed using an inverse-
variance weighted fixed-effects model.
Impact of a mother’s smoking intensity on offspring DNA
methylation
Further analyses were performed to investigate whether
the intensity of maternal smoking during pregnancy had
a differential impact on the level of offspring blood DNA
methylation. For this, the association between the num-
ber of cigarettes smoked per day during pregnancy and
offspring blood DNA methylation was assessed in the
NFBC studies. The association with the number of ciga-
rettes smoked and offspring blood DNA methylation
was assessed using linear regression with the same co-
variates as in the main analysis and meta-analyzed using
an inverse variance weighted fixed-effects model.
Negative control design to distinguish intrauterine effects
from confounding
Potential unmeasured confounding was examined in the
NFBC studies by using paternal smoking status during
pregnancy as a negative control. This method compares
the associations of maternal and paternal smoking dur-
ing pregnancy with offspring methylation outcomes. Use
of paternal smoking as a negative control is based on the
assumption that the biological effects of paternal smok-
ing on intrauterine exposure are negligible compared to
the effects of maternal smoking during pregnancy. If
there is an intrauterine effect of cigarette smoke expos-
ure, the associations are expected to be stronger for ma-
ternal smoking than paternal smoking behavior. If
effects are of similar magnitude, the associations be-
tween maternal smoking during pregnancy and offspring
methylation are likely attributable to unmeasured con-
founding, either by shared environmental or genetic fac-
tors [47]. The association with exposure to paternal
smoking and offspring blood DNA methylation was
assessed using linear regression with the same covariates
as in the main analysis and meta-analyzed using an
inverse-variance weighted fixed-effects model.
Persistence of DNA methylation into adulthood
We also examined whether the methylation changes as-
sociated with maternal smoking persisted into middle
age. DNA methylation data were available at two time
points in NFBC 1966 (age 31 years and 46 years) and
ALSPAC mother (age 30 years and 48 years). Generalized
least squares were used to examine the longitudinal
change in association between exposure to maternal
smoking and blood DNA methylation. DNA methylation
at each time point was regressed on the technical and
white blood cell covariates, and the corresponding resid-
uals were used as the outcome. Study-specific covariates
(offspring sex, smoking, BMI, and social class at each
time point in NFBC1966; maternal age, social class, and
offspring age and smoking status at each time point in
ALSPAC) were added in the model. Time point of meas-
urement and its interaction with the exposure were
added as additional terms to the regression model, and
the model residuals were allowed to be correlated within
each individual and be heteroskedastic between time
points. The effect estimates at both time points can be
derived from this model, and the test for equality of the
estimates at both time points is equivalent to testing the
interaction term being equal to zero [48]. The analyses
were conducted separately in NFBC1966 and ALSPAC
mothers and meta-analyzed using an inverse-variance
weighted fixed-effects model.
Mendelian randomization analysis for the effect of DNA
methylation on disease outcomes
We next sought to assess the potential causal relation-
ship between DNA methylation as the exposure and
106 different diseases as outcomes available through
the MR-Base platform (available at http://www.mrbase.
org/) using two-sample Mendelian randomization (MR)
. The two-sample MR approach uses gene-exposure
and gene-outcome associations from different data
sources of comparable populations and allows the inter-
rogation of summary estimates available from large
genome-wide association study (GWAS) consortia [24].
If instrumental variable assumptions for the genes asso-
ciated with the exposure are fulfilled [49], then MR es-
timates can give evidence for a causal effect of
exposure on the outcome.
We first looked up proxy single nucleotide poly-
morphisms (SNPs) for each of the 69 top maternal
smoking-associated CpG sites in the publicly avail-
able ARIES database containing methylation quanti-
tative trait loci (mQTL) at four different life stages
(birth, childhood, adolescence, middle age) in human
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blood [42]. We selected SNPs associated with each
CpG at P < 10−7 at any of the other four time
points. After clumping SNPs (using 1-Mb window
and R2 < 0.001) and pruning the CpG sites to one
per locus, we found strong instruments for 15 CpG
sites (Additional file 6). These SNP-CpG associations
were consistent across all time points (Additional file
7), except rs4306016-cg01825213 association, which
was excluded from the final MR analysis. We se-
lected the SNP-CpG and SNP-disease effect sizes at
middle age and aligned these to the same allele. MR
effect estimates were then calculated using Wald ra-
tio or, in case of cg04598670, which had two SNP
instruments available, inverse-variance weighted
method. The resulting effect estimate represents the
change in outcome per unit increase in the
exposure.
Mediation analysis
The CpGs that showed evidence for causal relation-
ship with disease outcomes in the MR analysis were
tested for mediation in the association between ma-
ternal smoking during pregnancy and disease out-
comes using the NFBC1966 data at 31 years and 46
years. We performed model-based causal mediation
analysis using R package “mediation” [50] by first es-
timating both the effect of maternal smoking on the
CpG site and the effect of CpG site on the outcome,
adjusted for exposure to maternal smoking (Fig. 6).
Both of these effects were additionally adjusted for
sex, offspring’s own smoking, and technical covari-
ates. We generated the estimates for the total effect,
average direct effect, and average causal mediation
effect using quasi-Bayesian Monte Carlo method
based on normal approximation with 2000 simula-
tions, with robust standard errors. The proportion
that the mediating CpG explains of the association
between maternal smoking and disease outcome was
calculated as described [51].
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